Cognitive impairment and dementia in Parkinson's disease

Neurobiology of Disease

Volumn 46, Issue 3, 2012, Pages 590-596

  Pagonabarraga, Javier ^a,b   Kulisevsky, Jaime ^a,b  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

Author keywords

Cognition; Dementia; Mild cognitive impairment; Parkinson's disease

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA;

ALPHA SYNUCLEIN GENE; ATTENTION DISTURBANCE; BRAIN ATROPHY; COGNITIVE DEFECT; DAYTIME SOMNOLENCE; DEMENTIA; EXECUTIVE DYSFUNCTION; GENE; GENE MUTATION; HALLUCINATION; HUMAN; LANGUAGE DISABILITY; MEMORY DISORDER; MILD COGNITIVE IMPAIRMENT; NEUROIMAGING; NEUROPATHOLOGY; NEUROPSYCHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PATHOPHYSIOLOGY; PHENOMENOLOGY; PREFRONTAL CORTEX; PREVALENCE; PRIORITY JOURNAL; REVIEW; SPEECH DISORDER;

ATROPHY; BRAIN; BRAIN CHEMISTRY; COGNITION DISORDERS; DEMENTIA; HUMANS; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE;

EID: 84860806544     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2012.03.029     Document Type: Review

References (111)

1. Aarsland D., Andersen K., Larsen J.P., Lolk A., Kragh-Sorensen P. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch. Neurol. 2003, 60:387-392.
2. Aarsland D., et al. The rate of cognitive decline in Parkinson disease. Arch. Neurol. 2004, 61:1906-1911.
3. Aarsland D., Zaccai J., Brayne C. A systematic review of prevalence studies of dementia in Parkinson's disease. Mov. Disord. 2005, 20:1255-1263.
4. Aarsland D., Bronnick K., Larsen J.P., Tysnes O.B., Alves G. Cognitive impairment in incident, untreated Parkinson disease: the Norwegian ParkWest study. Neurology 2009, 72:1121-1126.
5. Aarsland D., et al. Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis. Neurology 2010, 75:1062-1069.
6. Aarsland D., Muniz G., Matthews F. Nonlinear decline of mini-mental state examination in Parkinson's disease. Mov. Disord. 2011, 26:334-337.
7. Alexander G.E., DeLong M.R., Strick P.L. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu. Rev. Neurosci. 1986, 9:357-381.
8. Apaydin H., Ahlskog J.E., Parisi J.E., Boeve B.F., Dickson D.W. Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response. Arch. Neurol. 2002, 59:102-112.
9. Artero S., Petersen R., Touchon J., Ritchie K. Revised criteria for mild cognitive impairment: validation within a longitudinal population study. Dement. Geriatr. Cogn. Disord. 2006, 22:465-470.
10. Asahina M., et al. Brain muscarinic receptors in progressive supranuclear palsy and Parkinson's disease: a positron emission tomographic study. J. Neurol. Neurosurg. Psychiatry 1998, 65:155-163.
11. Azuma T., Cruz R.F., Bayles K.A., Tomoeda C.K., Montgomery E.B. A longitudinal study of neuropsychological change in individuals with Parkinson's disease. Int. J. Geriatr. Psychiatry. 2003, 18:1115-1120.
12. Ball B. De l'insanite dans la paralysie agitante. Encephale 1882, 2:22-32.
13. Ballard C., et al. Differences in neuropathologic characteristics across the Lewy body dementia spectrum. Neurology 2006, 67:1931-1934.
14. Balleine B.W., O'Doherty J.P. Human and rodent homologies in action control: corticostriatal determinants of goal-directed and habitual action. Neuropsychopharmacology 2010, 35:48-69.
15. Bastiaanse R., Leenders K.L. Language and Parkinson's disease. Cortex 2009, 45:912-914.
16. Bierman E.J., Comijs H.C., Jonker C., Beekman A.T. Effects of anxiety versus depression on cognition in later life. Am. J. Geriatr. Psychiatry. 2005, 13:686-693.
17. Boddy F., et al. Subjectively reported sleep quality and excessive daytime somnolence in Parkinson's disease with and without dementia, dementia with Lewy bodies and Alzheimer's disease. Int. J. Geriatr. Psychiatry. 2007, 22:529-535.
18. Bohnen N.I., Albin R.L. Cholinergic denervation occurs early in Parkinson disease. Neurology 2009, 73:256-257.
19. Bohnen N.I., Albin R.L. The cholinergic system and Parkinson disease. Behav. Brain Res. 2011, 221:564-573.
20. Bohnen N.I., et al. Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Arch. Neurol. 2003, 60:1745-1748.
21. Bohnen N.I., et al. Cognitive correlates of cortical cholinergic denervation in Parkinson's disease and parkinsonian dementia. J. Neurol. 2006, 253:242-247.
22. Braak H., et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 2003, 24:197-211.
23. Bronnick K., Alves G., Aarsland D., Tysnes O.B., Larsen J.P. Verbal memory in drug-naive, newly diagnosed Parkinson's disease. The retrieval deficit hypothesis revisited. Neuropsychology 2011, 25:114-124.
24. Burton E.J., McKeith I.G., Burn D.J., Williams E.D., O'Brien J.T. Cerebral atrophy in Parkinson's disease with and without dementia: a comparison with Alzheimer's disease, dementia with Lewy bodies and controls. Brain 2004, 127:791-800.
25. Burton E.J., McKeith I.G., Burn D.J., O'Brien J.T. Brain atrophy rates in Parkinson's disease with and without dementia using serial magnetic resonance imaging. Mov. Disord. 2005, 20:1571-1576.
26. Butterfield L.C., Cimino C.R., Oelke L.E., Hauser R.A., Sanchez-Ramos J. The independent influence of apathy and depression on cognitive functioning in Parkinson's disease. Neuropsychology 2010, 24:721-730.
27. Calabresi P., Picconi B., Parnetti L., Di Filippo M. A convergent model for cognitive dysfunctions in Parkinson's disease: the critical dopamine-acetylcholine synaptic balance. Lancet Neurol. 2006, 5:974-983.
28. Caviness J.N., et al. Defining mild cognitive impairment in Parkinson's disease. Mov. Disord. 2007, 22:1272-1277.
29. Charcot J., Vulpian A. De la paralysie agitante. Gaz. Hebd. Med. Chir. 1861, 8:756-767.
30. Clarimon J., et al. Early-onset familial lewy body dementia with extensive tauopathy: a clinical, genetic, and neuropathological study. J. Neuropathol. Exp. Neurol. 2009, 68:73-82.
31. Compta Y., et al. Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important?. Brain 2011, 134:1493-1505.
32. Cooper J.A., et al. Different effects of dopaminergic and anticholinergic therapies on cognitive and motor function in Parkinson's disease. A follow-up study of untreated patients. Brain 1992, 115(Pt 6):1701-1725.
33. Cummings J.L. Intellectual impairment in Parkinson's disease: clinical, pathologic, and biochemical correlates. J. Geriatr. Psychiatry Neurol. 1988, 1:24-36.
34. Cummings J.L. Frontal-subcortical circuits and human behavior. Arch. Neurol. 1993, 50:873-880.
35. Dubois B., Pilon B., Lhermitte F., Agid Y. Cholinergic deficiency and frontal dysfunction in Parkinson's disease. Ann. Neurol. 1990, 28:117-121.
36. Dujardin K., Sockeel P., Delliaux M., Destee A., Defebvre L. Apathy may herald cognitive decline and dementia in Parkinson's disease. Mov. Disord. 2009, 24:2391-2397.
37. Fenelon G., Mahieux F., Huon R., Ziegler M. Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors. Brain 2000, 123(Pt 4):733-745.
38. Filoteo J.V., et al. Variable memory profiles in Parkinson's disease. J. Clin. Exp. Neuropsychol. 1997, 19:878-888.
39. Galvin J.E., Pollack J., Morris J.C. Clinical phenotype of Parkinson disease dementia. Neurology 2006, 67:1605-1611.
40. Gjerstad M.D., Aarsland D., Larsen J.P. Development of daytime somnolence over time in Parkinson's disease. Neurology 2002, 58:1544-1546.
41. Goetz C.G., Leurgans S., Pappert E.J., Raman R., Stemer A.B. Prospective longitudinal assessment of hallucinations in Parkinson's disease. Neurology 2001, 57:2078-2082.
42. Goris A., et al. Tau and alpha-synuclein in susceptibility to, and dementia in, Parkinson's disease. Ann. Neurol. 2007, 62:145-153.
43. Gotham A.M., Brown R.G., Marsden C.D. 'Frontal' cognitive function in patients with Parkinson's disease 'on' and 'off' levodopa. Brain 1988, 111(Pt 2):299-321.
44. Halliday G. Clarifying the pathological progression of Parkinson's disease. Acta Neuropathol. 2008, 115:377-378.
45. Halliday G., Hely M., Reid W., Morris J. The progression of pathology in longitudinally followed patients with Parkinson's disease. Acta Neuropathol. 2008, 115:409-415.
46. Hely M.A., Reid W.G., Adena M.A., Halliday G.M., Morris J.G. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20years. Mov. Disord. 2008, 23:837-844.
47. Henry J.D., Crawford J.R. Verbal fluency deficits in Parkinson's disease: a meta-analysis. J. Int. Neuropsychol. Soc. 2004, 10:608-622.
48. Hilker R., et al. Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways. Neurology 2005, 65:1716-1722.
49. Hobson P., Meara J. Risk and incidence of dementia in a cohort of older subjects with Parkinson's disease in the United Kingdom. Mov. Disord. 2004, 19:1043-1049.
50. Huang X., Chen P., Kaufer D.I., Troster A.I., Poole C. Apolipoprotein E and dementia in Parkinson disease: a meta-analysis. Arch. Neurol. 2006, 63:189-193.
51. Huber S.J., Shuttleworth E.C., Freidenberg D.L. Neuropsychological differences between the dementias of Alzheimer's and Parkinson's diseases. Arch. Neurol. 1989, 46:1287-1291.
52. Hughes T.A., et al. A 10-year study of the incidence of and factors predicting dementia in Parkinson's disease. Neurology 2000, 54:1596-1602.
53. Hurtig H.I., et al. Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease. Neurology 2000, 54:1916-1921.
54. Janvin C.C., Larsen J.P., Aarsland D., Hugdahl K. Subtypes of mild cognitive impairment in Parkinson's disease: progression to dementia. Mov. Disord. 2006, 21:1343-1349.
55. Jellinger K.A. Alpha-synuclein pathology in Parkinson's and Alzheimer's disease brain: incidence and topographic distribution-a pilot study. Acta Neuropathol. 2003, 106:191-201.
56. Kehagia A.A., Barker R.A., Robbins T.W. Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease. Lancet Neurol. 2010, 9:1200-1213.
57. Klein J.C., et al. Neurotransmitter changes in dementia with Lewy bodies and Parkinson disease dementia in vivo. Neurology 2010, 74:885-892.
58. Kuhl D.E., et al. In vivo mapping of cholinergic terminals in normal aging, Alzheimer's disease, and Parkinson's disease. Ann. Neurol. 1996, 40:399-410.
59. Kulisevsky J. Role of dopamine in learning and memory: implications for the treatment of cognitive dysfunction in patients with Parkinson's disease. Drugs Aging 2000, 16:365-379.
60. Kulisevsky J., et al. Acute effects of levodopa on neuropsychological performance in stable and fluctuating Parkinson's disease patients at different levodopa plasma levels. Brain 1996, 119(Pt 6):2121-2132.
61. Kulisevsky J., et al. Chronic effects of dopaminergic replacement on cognitive function in Parkinson's disease: a two-year follow-up study of previously untreated patients. Mov. Disord. 2000, 15:613-626.
62. Kulisevsky J., Pagonabarraga J., Pascual-Sedano B., Garcia-Sanchez C., Gironell A. Prevalence and correlates of neuropsychiatric symptoms in Parkinson's disease without dementia. Mov. Disord. 2008, 23:1889-1896.
63. Lees A.J., Smith E. Cognitive deficits in the early stages of Parkinson's disease. Brain 1983, 106(Pt 2):257-270.
64. Levy G., et al. Combined effect of age and severity on the risk of dementia in Parkinson's disease. Ann. Neurol. 2002, 51:722-729.
65. Lewis S.J., et al. Using executive heterogeneity to explore the nature of working memory deficits in Parkinson's disease. Neuropsychologia 2003, 41:645-654.
66. Lewy F. Die Lehre vom Tonus und der Bewegung. Monogr. Neurol. Psychiatr. 1923, 34:32-45.
67. Linazasoro G., Lasa A., Van Blercom N. Efficacy and safety of donepezil in the treatment of executive dysfunction in Parkinson disease: a pilot study. Clin. Neuropharmacol. 2005, 28:176-178.
68. Llebaria G., et al. Neuropsychological correlates of mild to severe hallucinations in Parkinson's disease. Mov. Disord. 2010, 25:2785-2791.
69. Mahieux F., et al. Neuropsychological prediction of dementia in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 1998, 64:178-183.
70. Martinez-Horta S., Kulisevsky J. Is all cognitive impairment in Parkinson's disease "mild cognitive impairment"?. J. Neural Transm. 2011, 118:1185-1190.
71. Marttila R.J., Rinne U.K. Dementia in Parkinson's disease. Acta Neurol. Scand. 1976, 54:431-441.
72. Masliah E., et al. beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:12245-12250.
73. Matison R., Mayeux R., Rosen J., Fahn S. "Tip-of-the-tongue" phenomenon in Parkinson disease. Neurology 1982, 32:567-570.
74. Mattila P.M., Rinne J.O., Helenius H., Dickson D.W., Roytta M. Alpha-synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson's disease. Acta Neuropathol. 2000, 100:285-290.
75. McKinlay A., Grace R.C., Dalrymple-Alford J.C., Roger D. Characteristics of executive function impairment in Parkinson's disease patients without dementia. J. Int. Neuropsychol. Soc. 2010, 16:268-277.
76. Mjönes H. Paralysis agitans: a clinical and genetic study. Acta Psychiatr. Neurol. Scand. 1949, 54:195.
77. Monchi O., et al. Neural bases of set-shifting deficits in Parkinson's disease. J. Neurosci. 2004, 24:702-710.
78. Monchi O., Petrides M., Mejia-Constain B., Strafella A.P. Cortical activity in Parkinson's disease during executive processing depends on striatal involvement. Brain 2007, 130:233-244.
79. Morris R.G., et al. Planning and spatial working memory in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 1988, 51:757-766.
80. Mosimann U.P., et al. Visual perception in Parkinson disease dementia and dementia with Lewy bodies. Neurology 2004, 63:2091-2096.
81. Muslimovic D., Post B., Speelman J.D., Schmand B. Cognitive profile of patients with newly diagnosed Parkinson disease. Neurology 2005, 65:1239-1245.
82. Muslimovic D., Post B., Speelman J.D., De Haan R.J., Schmand B. Cognitive decline in Parkinson's disease: a prospective longitudinal study. J. Int. Neuropsychol. Soc. 2009, 15:426-437.
83. Nagano-Saito A., et al. Cerebral atrophy and its relation to cognitive impairment in Parkinson disease. Neurology 2005, 64:224-229.
84. Nakano I., Hirano A. Parkinson's disease: neuron loss in the nucleus basalis without concomitant Alzheimer's disease. Ann. Neurol. 1984, 15:415-418.
85. Neumann J., et al. Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. Brain 2009, 132:1783-1794.
86. Noe E., et al. Comparison of dementia with Lewy bodies to Alzheimer's disease and Parkinson's disease with dementia. Mov. Disord. 2004, 19:60-67.
87. Owen A.M., Iddon J.L., Hodges J.R., Summers B.A., Robbins T.W. Spatial and non-spatial working memory at different stages of Parkinson's disease. Neuropsychologia 1997, 35:519-532.
88. Pagonabarraga J., et al. Parkinson's disease-cognitive rating scale: a new cognitive scale specific for Parkinson's disease. Mov. Disord. 2008, 23:998-1005.
89. Pillon B., et al. Cognitive slowing in Parkinson's disease fails to respond to levodopa treatment: the 15-objects test. Neurology 1989, 39:762-768.
90. Pillon B., et al. Does cognitive impairment in Parkinson's disease result from non-dopaminergic lesions?. J. Neurol. Neurosurg. Psychiatry 1989, 52:201-206.
91. Pletnikova O., et al. Abeta deposition is associated with enhanced cortical alpha-synuclein lesions in Lewy body diseases. Neurobiol. Aging 2005, 26:1183-1192.
92. Plowey E.D., Chu C.T. Synaptic dysfunction in genetic models of Parkinson's disease: a role for autophagy?. Neurobiol. Dis. 2011, 43:60-67.
93. Poewe W., Berger W., Benke T., Schelosky L. High-speed memory scanning in Parkinson's disease: adverse effects of levodopa. Ann. Neurol. 1991, 29:670-673.
94. Pollock M., Hornabrook R.W. The prevalence, natural history and dementia of Parkinson's disease. Brain 1966, 89:429-448.
95. Raskin S.A., Borod J.C., Tweedy J. Neuropsychological aspects of Parkinson's disease. Neuropsychol. Rev. 1990, 1:185-221.
96. Schulz-Schaeffer W.J. The synaptic pathology of alpha-synuclein aggregation in dementia with Lewy bodies, Parkinson's disease and Parkinson's disease dementia. Acta Neuropathol. 2010, 120:131-143.
97. Seto-Salvia N., et al. Dementia risk in Parkinson disease: disentangling the role of MAPT haplotypes. Arch. Neurol. 2011, 68:359-364.
98. Sidransky E., et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N. Engl. J. Med. 2009, 361:1651-1661.
99. Somme J.H., et al. Initial neuropsychological impairments in patients with the E46K mutation of the alpha-synuclein gene (PARK 1). J. Neurol. Sci. 2011, 310:86-89.
100. Spillantini M.G., et al. Alpha-synuclein in Lewy bodies. Nature 1997, 388:839-840.
101. Spillantini M.G., Crowther R.A., Jakes R., Hasegawa M., Goedert M. Alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:6469-6473.
102. Starkstein S.E., et al. Depression and cognitive impairment in Parkinson's disease. Brain 1989, 112(Pt 5):1141-1153.
103. Starkstein S.E., et al. Neuropsychological and psychiatric differences between Alzheimer's disease and Parkinson's disease with dementia. J. Neurol. Neurosurg. Psychiatry 1996, 61:381-387.
104. Troster A.I. Neuropsychological characteristics of dementia with Lewy bodies and Parkinson's disease with dementia: differentiation, early detection, and implications for "mild cognitive impairment" and biomarkers. Neuropsychol. Rev. 2008, 18:103-119.
105. Varanese S., Perfetti B., Ghilardi M.F., Di Rocco A. Apathy, but not depression, reflects inefficient cognitive strategies in Parkinson's disease. PLoS One 2011, 6:e17846.
106. Weintraub D., Moberg P.J., Culbertson W.C., Duda J.E., Stern M.B. Evidence for impaired encoding and retrieval memory profiles in Parkinson disease. Cogn. Behav. Neurol. 2004, 17:195-200.
107. Whittington C.J., Podd J., Kan M.M. Recognition memory impairment in Parkinson's disease: power and meta-analyses. Neuropsychology 2000, 14:233-246.
108. Whittington C.J., Podd J., Stewart-Williams S. Memory deficits in Parkinson's disease. J. Clin. Exp. Neuropsychol. 2006, 28:738-754.
109. Whitwell J.L., et al. Focal atrophy in dementia with Lewy bodies on MRI: a distinct pattern from Alzheimer's disease. Brain 2007, 130:708-719.
110. Williams-Gray C.H., et al. The distinct cognitive syndromes of Parkinson's disease: 5year follow-up of the CamPaIGN cohort. Brain 2009, 132:2958-2969.
111. Zarranz J.J., et al. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 2004, 55:164-173.